Statin Use Exposure | Cases (n = 231) | Controls (n = 15,575) | Odds Ratios (95% Confidence Intervals) |
|---|
n | % | n | % | Unadjusted | Adjusted |
|---|
No Use | 83 | 35.9 | 6181 | 39.7 | 1.0 (referent) | 1.0 (referent) |
Any Use | 148 | 64.1 | 9394 | 60.3 | 1.17 (0.89–1.54) | 0.89 (0.67–1.19) |
Lesser Use (PDC <80%) | 62 | 26.8 | 4111 | 26.4 | 1.16 (0.83–1.62) | 0.93 (0.66–1.31) |
Higher Use (PDC >80%) | 86 | 37.2 | 5283 | 33.9 | 1.18 (0.86–1.61) | 0.87 (0.63–1.20) |
- Note: Separate models were fit to study i) any statin use, or ii) lesser and higher statin use compared with no statin use
- From conditional logistic regression models of cases and control sets matched on age (±3 years), sex, race, and time since kidney transplant (±1 year). Adjusted models controlled for Hispanic ethnicity, body mass index, time since incident end-stage renal disease, comorbidities (diabetes, cardiovascular disease, cerebrovascular disease, arrhythmia, rheumatologic disease), transplant related factors (living vs. deceased donor, history of acute rejection, maximum panel-reactive antibody titer), and individual immunosuppressant drugs used in the year prior to the index date (tacrolimus, cyclosporine, mycophenolate mofetil/mycophenolic acid, azathioprine, sirolimus/everolimus, corticosteroids)
